FlagInternationalUnited States
 

Overview

Corporate Profile

Uroplasty, Inc. is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices.

Uroplasty products are typically used when a patient’s treatment goals are not met after conservative and/or drug therapies. Providers and patients alike appreciate that Uroplasty products provide low-risk, effective alternatives to invasive surgery. And because these treatments can be delivered in an office or outpatient setting, the end result is that more patients are given the opportunity to transform their lives with successful treatment.

 
Stock Quote
UPI (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$1.22
Change (%) Stock is Up 0.01 (0.83%)
Volume196,216
Data as of 03/03/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
03/03/15Uroplasty to Host Investor Meeting at Corporate Headquarters
March 12th Event to Feature Urologist Perspective on the Use of Uroplasty and Vision-Sciences Product Lines MINNEAPOLIS, March 3, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, will host a meeting for shareholders and analysts on Thursday, March 12, 2015, beginning at 3:00 pm Central Time, at Uroplasty's corporate headquarters in Minnetonka, Minnesota.     ... 
 Printer Friendly Version
02/27/15Uroplasty to Participate in the 27th Annual ROTH Conference
MINNEAPOLIS, Feb. 27, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that it will participate in the 27th Annual ROTH Conference on Tuesday, March 10, 2015. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 4:00 p.m. Pacific Time and meet with investors one on one at the conference at the Ritz Carlton in Lagun... 
 Printer Friendly Version
02/24/15Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Cigna
MINNEAPOLIS, Feb. 24, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that Cigna has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent(R) PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontin... 
 Printer Friendly Version
01/22/15Uroplasty Reports Record Revenue in Fiscal Third Quarter
~ Global Urgent PC Sales Up 14.5% ~~ Proposed Merger with Vision-Sciences to Expand Innovation in Product Portfolio MINNEAPOLIS, Jan. 22, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fiscal 2015 third quarter ended December 31, 2014.  Global revenue for the Company's Urgent® PC Neuromodulation System grew 14.5% ... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Uroplasty, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.